Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240024/S001

Genio System 2.1

Nyxoah S.A. · Decision date Oct 3, 2025

FDA DECISIONP240024/S001

What did the FDA approve?

FDA records P240024/S001 as a supplement to PMA P240024, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Oct 3, 2025.

FDA approval order statement

approval of the Post Approval Study protocol for the New Enrollment Study (BREATHE Study)
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Anesthesiology
Decision date
Oct 3, 2025
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P240024/S001
Regulatory pathway
PMA supplement
Applicant
Nyxoah S.A.
Product code
MNQ
Decision code
APPR
Decision date
Oct 3, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, hypoglossal nerve, implanted, apnea.

Applicant
Nyxoah S.A.
Product code
MNQ
FDA device class
3

For the original device and its historical approval scope, see PMA P240024. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240024 · Original PMA

    Genio System 2.1

  2. P240024/S001 received

    Application receipt date recorded by FDA.

  3. P240024/S001 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P240024. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240024

Product / regulatory recordCompanyPathwayDecision dateSource
Nyxoah S.A.PMA approvalAug 8, 2025FDA
Genio System 2.1P240024/S002
Nyxoah S.A.PMA supplementNov 6, 2025FDA
Genio System 2.1P240024/S003
Nyxoah S.A.PMA supplementJun 8, 2026FDA
Genio System 2.1P240024/S004
Nyxoah S.A.PMA supplementJul 30, 2026FDA

Explore the linked device profile

Other records with product code MNQ

Product / regulatory recordCompanyPathwayDecision dateSource
Inspire Medical SystemsPMA supplementNov 5, 2026FDA
Inspire Medical SystemsPMA supplementOct 26, 2026FDA
Model 3150 IPGP130008/S147
Inspire Medical SystemsPMA supplementOct 22, 2026FDA
Model 3150 IPGP130008/S146
Inspire Medical SystemsPMA supplementOct 13, 2026FDA
Inspire Medical SystemsPMA supplementAug 28, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Nyxoah S.A.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Rue Edouard Belin, 12, Mont-Saint-Guibert, 1435

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records